公开(公告)号：US20240075129A1

公开(公告)日：2024-03-07

申请号：US18488629

申请日：2023-10-17

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC: A61K39/215 ,  C12N15/861

CPC classification number: A61K39/215 ,  C12N15/861 ,  A61P31/14

Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US11857620B2

公开(公告)日：2024-01-02

申请号：US17198164

申请日：2021-03-10

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC: A61K39/215 ,  A61K39/39 ,  C12N15/86 ,  A61P31/14 ,  A61K39/00

CPC classification number: A61K39/215 ,  A61K39/39 ,  C12N15/86 ,  A61K2039/545 ,  A61K2039/55505 ,  A61P31/14 ,  C12N2710/10343 ,  C12N2770/20022 ,  C12N2770/20034

Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20230338508A9

公开(公告)日：2023-10-26

申请号：US17198164

申请日：2021-03-10

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC: A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86 ,  A61K2039/55505

Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20230183770A1

公开(公告)日：2023-06-15

申请号：US17931352

申请日：2022-09-12

Applicant: ImmunityBio, Inc.

Inventor： Brett Morimoto ,  Kayvan Niazi ,  Annie Shin ,  Lise Geissert ,  Philip T. Liu

IPC: C12P19/34 ,  C12N9/12

CPC classification number: C12P19/34 ,  C12N9/1247 ,  C12N9/1241 ,  C12Y207/07019

Abstract: A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.

公开(公告)号：US20230086390A1

公开(公告)日：2023-03-23

申请号：US17198164

申请日：2021-03-10

Applicant: ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC: A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86

Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20220257660A1

公开(公告)日：2022-08-18

申请号：US17732190

申请日：2022-04-28

Applicant: NantCell, Inc. ,  NantBio, Inc. ,  ImmunityBio, Inc.

Inventor： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Hans G. Klingemann

IPC: A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  C07K14/54

Abstract: Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

公开(公告)号：US20220187279A1

公开(公告)日：2022-06-16

申请号：US17544586

申请日：2021-12-07

Applicant: ImmunityBio, Inc.

Inventor： Peter Allan Sieling ,  Kayvan Niazi ,  Helty Adisetiyo ,  Philip T. Liu

IPC: G01N33/50

Abstract: Methods for detecting the presence of sever acute respiratory coronavirus 2 (SARS-CoV-2) are provided. The methods comprise incubating a sample comprising T-cells from an individual with one or more SARS-CoV-2 antigens, each antigen having a T-cell epitope, and detecting a change in state of T-cells in the sample. The change in state may be detected by determining the presence or level of a secreted, immune response indicator, such as interferon-gamma (IFN-γ).

公开(公告)号：US20210284716A1

公开(公告)日：2021-09-16

申请号：US16880804

申请日：2020-05-21

Applicant: ImmunityBio, Inc.

Inventor： Kayvan Niazi ,  C. Anders Olson ,  Shiho Tanaka ,  John H. Lee ,  Wendy Higashide ,  Patrick Soon-Shiong

IPC: C07K14/81

Abstract: An ACE2-Fc hybrid construct is used as a therapeutic and/or analytic entity to treat an individual infected with a coronavirus or to detect a coronavirus in an analyte. In selected embodiments, the Fc portion of the hybrid construct is an IgA Fc portion, and in still further embodiments the ACE2 portion has a mutation that reduces or abolishes ACE2 catalytic activity.

公开(公告)号：US20210284713A1

公开(公告)日：2021-09-16

申请号：US17082994

申请日：2020-10-28

Applicant: ImmunityBio, Inc.

Inventor： Kayvan Niazi ,  Jay Gardner Nelson ,  Annie Shin ,  Clifford Anders Olson ,  Shiho Tanaka

IPC: C07K14/705 ,  C07K14/005 ,  C12N15/86 ,  A61K39/215

Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.

公开(公告)号：US20210283245A1

公开(公告)日：2021-09-16

申请号：US16883263

申请日：2020-05-26

Applicant: ImmunityBio, Inc. ,  GlobeImmune, Inc

Inventor： Kayvan Niazi ,  Thomas King

IPC: A61K39/235 ,  C07K14/165 ,  C12N1/16

Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.